Critical Outcome Technologies Receives Orphan Drug Designation For COTI-2

LONDON, ONTARIO (Marketwired Jun 17, 2014) - Critical Outcome Technologies Inc. ( COTI or the Company ) (TSX VENTURE:COT)(OTCQB:COTQF), the bioinformatics and accelerated drug discovery company, announced today that the U.S. Food and Drug Administration (FDA) has granted COTI-2 an Orphan Drug Designation for the treatment of ovarian cancer. Receiving the Orphan Drug Designation for COTI-2 speaks to the need for new treatment options for patients with ovarian cancer, said Dr. Wayne Danter, President and CEO. When current first line treatments fail, oncologists have limited treatment options to offer these patients. With its p53 dependent mechanism of action, COTI-2 is a novel compound with the potential to benefit these patients, as more than 95% of serious ovarian cancers have a p53 gene mutation. We continue to believe that COTI-2 could represent a significant therapeutic advantage over treatments currently available for ovarian and other gynecological cancers. This is an important
http://bit.ly/1yebroJ